Bernstein raised the firm’s price target on Gilead (GILD) to $135 from $120 and keeps an Outperform rating on the shares. Gilead reported Q2 revenue and EPS that slightly beat estimates, while the full year guidance was raised as HIV performed better than expected, the analyst tells investors in a research note. The firm says Yeztugo is off to a “great” start.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GILD:
- Gilead upgraded to Outperform from Neutral at Daiwa
- Gilead Sciences Appoints New Senior Vice President
- Gilead Sciences’ Phase 3 Study on Triple Negative Breast Cancer: A Potential Game-Changer?
- Gilead Sciences: Hold Rating Amidst Strong HIV Performance and Limited Growth Prospects
- Gilead Sciences: Strong Q2 Performance and Promising Yeztugo Launch Support Buy Rating